AU6290998A - 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use - Google Patents
4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and useInfo
- Publication number
- AU6290998A AU6290998A AU62909/98A AU6290998A AU6290998A AU 6290998 A AU6290998 A AU 6290998A AU 62909/98 A AU62909/98 A AU 62909/98A AU 6290998 A AU6290998 A AU 6290998A AU 6290998 A AU6290998 A AU 6290998A
- Authority
- AU
- Australia
- Prior art keywords
- thieno
- tetrahydro
- preparation
- pyridine derivatives
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK24997 | 1997-03-07 | ||
DK249/97 | 1997-03-07 | ||
DK136597 | 1997-11-27 | ||
DK1365/97 | 1997-11-27 | ||
PCT/DK1998/000083 WO1998040385A1 (en) | 1997-03-07 | 1998-03-06 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6290998A true AU6290998A (en) | 1998-09-29 |
Family
ID=26063610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU62909/98A Abandoned AU6290998A (en) | 1997-03-07 | 1998-03-06 | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0973778A1 (en) |
JP (1) | JP2001514631A (en) |
AU (1) | AU6290998A (en) |
WO (1) | WO1998040385A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999045013A1 (en) * | 1998-03-06 | 1999-09-10 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES |
US6090797A (en) * | 1998-09-02 | 2000-07-18 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno(2,3-C)pyridine derivatives |
AU5154699A (en) * | 1998-09-02 | 2000-03-27 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives |
US8481268B2 (en) | 1999-05-21 | 2013-07-09 | Illumina, Inc. | Use of microfluidic systems in the detection of target analytes using microsphere arrays |
US8080380B2 (en) | 1999-05-21 | 2011-12-20 | Illumina, Inc. | Use of microfluidic systems in the detection of target analytes using microsphere arrays |
DK1741445T3 (en) | 2000-01-21 | 2013-11-04 | Novartis Ag | Combinations comprising dipeptidyl peptidase IV inhibitors and antidiabetic agents |
UA74826C2 (en) | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
MXPA04000358A (en) | 2001-07-13 | 2004-05-04 | Pharmacia & Up John Company | Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands. |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
JP4564952B2 (en) * | 2003-01-17 | 2010-10-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment and prevention of diabetes |
US7138529B2 (en) * | 2003-04-16 | 2006-11-21 | Hoffmann-La Roche Inc. | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
HUE028976T2 (en) | 2003-06-17 | 2017-02-28 | Arena Pharm Inc | 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride |
CN1805939B (en) | 2003-06-17 | 2010-10-13 | 艾尼纳制药公司 | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
JP4820169B2 (en) | 2003-07-15 | 2011-11-24 | 大日本住友製薬株式会社 | New heteroaryl derivatives |
ATE420881T1 (en) | 2003-09-17 | 2009-01-15 | Janssen Pharmaceutica Nv | CONDENSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE SEROTONIN RECEPTOR |
DK1838677T3 (en) | 2004-12-21 | 2010-01-11 | Arena Pharm Inc | Crystalline forms of (R) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
WO2006109085A1 (en) * | 2005-04-13 | 2006-10-19 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
KR101352588B1 (en) | 2005-09-14 | 2014-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | Dipeptidyl peptidase inhibitors for treating diabetis |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
PE20080145A1 (en) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1 |
JP5199997B2 (en) | 2006-04-03 | 2013-05-15 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Process for preparing 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and related intermediates |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044054A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in therapy |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
JP5528806B2 (en) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | Compound drug |
JP5721949B2 (en) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Compound drug |
US8779132B2 (en) | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
SG177128A1 (en) | 2006-12-05 | 2012-01-30 | Arena Pharm Inc | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
PE20091102A1 (en) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 |
US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP2443080A2 (en) | 2009-06-18 | 2012-04-25 | Arena Pharmaceuticals, Inc. | Process for the preparation of 5-ht2c receptor agonists |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
PL2531501T3 (en) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Apoptosis signal-regulating kinase 1 inhibitors |
KR20130112848A (en) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | Processes for the preparation of 5-ht2c receptor agonists |
CN101863900B (en) * | 2010-06-29 | 2012-07-25 | 天津药物研究院 | Novel nitric oxide donating thienopyridine derivative and preparation method and application thereof |
CN103347523A (en) | 2010-09-01 | 2013-10-09 | 艾尼纳制药公司 | Administration of lorcaserin to individual with renal impairment |
EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
EP2611782A1 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
CA2808904A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
US9242994B2 (en) | 2012-03-23 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines |
MY181736A (en) | 2012-10-09 | 2021-01-05 | Arena Pharm Inc | Method of weight management |
EA031804B1 (en) | 2014-02-03 | 2019-02-28 | Вайтаи Фармасьютиклз, Инк. | Dihydropyrrolopyridine inhibitors of ror-gamma |
JP6564029B2 (en) | 2014-10-14 | 2019-08-21 | ヴァイティー ファーマシューティカルズ,エルエルシー | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
ES2856931T3 (en) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | ROR-gamma modulators |
EP3377482B1 (en) | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
TW202220968A (en) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | Modulators of ror-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US20200062776A1 (en) * | 2016-06-16 | 2020-02-27 | Memorial Sloan-Kettering Cancer Center | Hedgehog acyltransferase inhibitors and uses thereof |
AR112461A1 (en) | 2017-07-24 | 2019-10-30 | Vitae Pharmaceuticals Inc | PROCESSES FOR THE PRODUCTION OF SALTS AND CRYSTAL FORMS OF RORg INHIBITORS |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
US11267825B2 (en) | 2017-11-02 | 2022-03-08 | Aicuris Gmbh & Co. Kg | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) |
US20220177488A1 (en) * | 2019-03-19 | 2022-06-09 | Suvalent Therapeutics, Inc. | Sumo inhibitor compounds and uses thereof |
WO2023137297A2 (en) * | 2022-01-11 | 2023-07-20 | Suvalent Therapeutics, Inc. | 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo inhibitors and uses thereof |
CN114507155A (en) * | 2022-02-16 | 2022-05-17 | 浙江欣禾生物股份有限公司 | Preparation method of m-trifluoromethyl acetophenone oxime |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD210278A5 (en) * | 1982-03-05 | 1984-06-06 | Boehringer Ingelheim Kg | PROCESS FOR PREPARING NEW BASIC SUBSTITUTED 4-PHENYL-4,5,6,7-TETRAHYDRO-THIENO- (2,3-C) PYRIDINE |
DE3412947A1 (en) * | 1984-04-06 | 1985-10-17 | Bayer Ag, 5090 Leverkusen | TETRAHYDOTHIENOPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT |
GB8429087D0 (en) * | 1984-11-16 | 1984-12-27 | Scras | Thienopyridine derivatives |
FR2595356B1 (en) * | 1986-03-05 | 1991-05-24 | Pasteur Strasbourg Universite | DERIVATIVES OF NITRO OR AMINOBENZYLTETRAHYDROISOQUINOLEINS, PROCESSES FOR OBTAINING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, PHARMACOLOGICAL PROPERTIES AND APPLICATIONS |
FR2733750B1 (en) * | 1995-05-03 | 1997-06-13 | Synthelabo | DERIVATIVES OF GAMMA-OXO-ALPHA- (PHENYLMETHYL) -5,6- DIHYDRO-4H-THIENO (3,4-C) PYRROLE-5-BUTANOIQUE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
-
1998
- 1998-03-06 EP EP98906858A patent/EP0973778A1/en not_active Withdrawn
- 1998-03-06 JP JP53909998A patent/JP2001514631A/en active Pending
- 1998-03-06 WO PCT/DK1998/000083 patent/WO1998040385A1/en not_active Application Discontinuation
- 1998-03-06 AU AU62909/98A patent/AU6290998A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001514631A (en) | 2001-09-11 |
EP0973778A1 (en) | 2000-01-26 |
WO1998040385A1 (en) | 1998-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6290998A (en) | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use | |
IL119565A0 (en) | Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e] indol-8-ones derivatives thereof and their use | |
IL118825A (en) | Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use | |
IL116851A0 (en) | 3-arylidene-2-oxindole derivatives their preparation and use | |
IL118380A0 (en) | Substituted pyridine derivatives their preparation and use | |
IL132967A0 (en) | 3-Substituted 3,4-dihydro-thieno¬2,3-d¾pyrimidine derivatives and production and use of the same | |
PL332144A1 (en) | Derivatives of pyrido-[4',3':4,5]thiene[2,3-d]-pyrimidine substituted at position 3, their production and application | |
AU4559497A (en) | 1H-pyrido{3,4-b}indole-4-carboxamide derivatives, their preparation and their application in therapeutics | |
PL332382A1 (en) | Derivatives of 1,2,3,4-tetrahydro-benzofuro [3,2-c] pyridine | |
IL131645A (en) | Pyrimido ¬1,2-a¾indole derivatives and their preparation | |
ZA9725B (en) | 4,5-Dihydronaphth[1,2-c]isoxazoles and derivatives thereof | |
EG21121A (en) | 13 Substituted milbemycin derivatives their preparation and use | |
AU5154699A (en) | 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives | |
AU3693797A (en) | 1,3-dimethyl-5-fluoro-pyrazole-4-carboxamide derivatives, their preparation and their use as microbicides | |
AU2406597A (en) | Thienopyridine derivatives, their production and use | |
IL118443A0 (en) | Cycloalkane-benzylidene derivatives their preparation and use | |
AU2030197A (en) | 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof | |
AU2405397A (en) | Thienopyridine derivatives and their use | |
IL123092A0 (en) | Pyrazol-4-ylbenzoyl derivatives their preparation and use | |
IL132985A0 (en) | 3-Substituted pyrido ¬3'4':4,5¾thieno ¬2,3-d¾pyrimidine derivatives and production and use of the same | |
GB2324090B (en) | 5,6-O-alkylidene glucono-1(4)-lactones and derivatives thereof,their preparation and use | |
HUP0002659A3 (en) | Benzo-5,6-cyclohepta[1,2-b]pyridine derivatives, pharmaceutical compositions containing them and their use | |
AU1663399A (en) | Pyrido 1,2,4-thiadiazine derivatives, their preparation and use | |
ZA981965B (en) | 4,5,6,7-tetrahydro-thieno(3,2-C)pyridine derivatives their preparation and use | |
ZA953749B (en) | 5,6-dihydro-4H-thieno[3,4-c] pyrroie derivatives their preparation and their therapeutic application |